TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02749877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working Memory Training
Description: (Training Details already described above)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Working Memory Training
Description: (Training Details already described above)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Training
Description: (Training Details already described above)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Training
Description: (Training Details already described above)
Study: NCT02679378

Intervention type: DEVICE
Intervention: ClearSight™ System
Description: comparing ClearSight system to histopathological to determine negative-margins in breast conserving surgery.
Study: NCT02912728

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CGM + Family Behavioral Intervention
Description: use of CGM combined with a CGM focused family behavioral intervention and to assess CGM adherence

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard CGM
Description: use of CGM alone to assess CGM adherence
Study: NCT05152017

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu-M Quadro [inactivated split influenza vaccine] with preservative
Description: solution for intramuscular injection, 0.5 ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu-M Quadro [inactivated split influenza vaccine] without preservative
Description: solution for intramuscular injection, 0.5 ml

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: solution for intramuscular injection, 0.5 ml
Study: NCT00523341

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Administered by subcutaneous injection once every 6 months.
Study: NCT00857753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl patch 25 ug/nr Sandoz

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duragesic
Study: NCT03327181

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: short chain fatty acid tracers
Description: stable tracer infusion of acetate, propionate, and butyrate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: short chain fatty acid tracers
Description: stable tracer infusion of acetate, propionate, and butyrate
Study: NCT01833104

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Presence - Perspective - Affect
Description: PRESENCE: Cultivate attentional skills \& interoceptive body awareness. 2 exercises: Breathing Meditation \& Body Scan.~PERSPECTIVE: Focus on cognitive aspects of compassion; take perspectives on thoughts, the self, \& other people; observe more macroscopic dynamics within oneself, your inner parts; do not fully identify with them / be aware of their transiency; strengthen the ability to detach from one's own perspective, take the perspectives of others, trying to understand their thoughts, motives, feelings. 2 exercises: Observing-thoughts Meditation \& Perspective Dyad.~AFFECT: Cultivate emotional/motivational aspects of compassion; cultivate a sense of benevolence, love, care, opening the heart for oneself and others; work with obstacles, e.g. fear, anger or sadness (emotion acceptance); pro-social motivations as an alley towards loving / benevolent feelings and as a consequence of them. 2 exercises: Loving-kindness Meditation \& Affect Dyad.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Presence - Affect - Perspective.
Description: As specified above however the order is interchanged between the cohorts TC1 and TC2.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Affect
Description: AFFECT: Cultivate emotional/motivational aspects of compassion; cultivate a sense of benevolence, love, care, opening the heart for oneself and others; work with obstacles, e.g. fear, anger or sadness (emotion acceptance); pro-social motivations as an alley towards loving / benevolent feelings and as a consequence of them. 2 exercises: Loving-kindness Meditation \& Affect Dyad.
Study: NCT00796094

Intervention type: OTHER
Intervention: Ultrasound examination
Description: Sonoelastrography is an ultrasound examination that can determine the elasticity of soft tissue. This examination takes approximately 10 minutes to complete.
Study: NCT04895605

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia HLS Laser
Description: The Erchonia HLS Laser emits a 640 nm (nanometer) wavelength with a tolerance of ±10 nm from each of two 7.5 mw (milliwatt) laser diodes.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Laser
Description: The Placebo Laser emit the same visible light output as the active HLS Laser but without therapeutic effect.
Study: NCT04382898

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT112
Description: Intravenous bolus injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT112
Description: Intravenous bolus injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT112
Description: Intravenous bolus injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT112
Description: Intravenous bolus injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT112
Description: Intravenous bolus injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Intravenous infusion
Study: NCT00296361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: immunosuppression
Study: NCT03452189

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Oral vancomycin 250mg capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vancomycin
Description: Oral vancomycin 250mg capsules

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo Pills distributed by Research Pharmacy labeled placebo.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Pills distributed by Research Pharmacy labeled placebo.
Study: NCT03200626

Intervention type: PROCEDURE
Intervention: Autologous hematopoietic cell transplant
Description: Autologous hematopoietic cell transplant

Intervention type: PROCEDURE
Intervention: Autologous hematopoietic cell transplant
Description: Autologous hematopoietic cell transplant

Intervention type: PROCEDURE
Intervention: Autologous hematopoietic cell transplant
Description: Autologous hematopoietic cell transplant
Study: NCT00232349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: galantamine
Description: open label galantamine, dosed at 4-12 mg/b.i.d., with a target dose of 12 mg/b.i.d.
Study: NCT03344536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant will be administered according to its approved dose of 500 mg intramuscularly on days 1, 15, 29 and then every 28 days (+/-3 days) thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 1347
Description: Debio 1347 will be administered orally daily (1 cycle is 28 days) and the dose of Debio 1347 could be deescalated.
Study: NCT02818387

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil 0.125 mcg/kg/min infusion for 5 min before propofol administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Remifentanil 0.125 mcg/kg/min infusion for 5 min before propofol administration followed by midazolam 0.015 mg/kg administration 1 min after remifentanil infusion start.
Study: NCT01117337

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Mesh Fixation
Description: Laparoscopic Total extraperitoneal repair of Inguinal hernia under Spinal Anesthesia - Mesh is not fixed to any structure
Study: NCT04498741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-938
Description: Subjects will receive EDP-938 once daily on Days 10 through 27 (Part 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-938
Description: Subjects will receive EDP-938 once daily on Days 5 through 15 (Part 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-938
Description: Subjects will receive EDP-938 once daily on Days 5 through 15 (Part 3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Subjects will receive tacrolimus once daily on Day 1 and Day 24

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: Subjects will receive dabigatran once daily on Day 1 and Day 13

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Subjects will receive rosuvastatin once daily on Day 1 and Day 13

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-938
Description: Subjects will receive EDP-938 once daily on Days 3 through 16 (Part 4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Subjects will receive midazolam once daily on Day 1 and Day 16
Study: NCT04054128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate 7.5% Injection
Description: Sodium bicarbonate solution for catheter lock; 7.5% sodium bicarbonate solution will be used for catheter lock in both catheter lumens, 1.9 mL in each catheter lumen will be infused after hemodialysis treatment during 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin Sodium, 1000 Units/mL Injectable Solution 1
Description: Heparin for catheter lock: 1000 u/mL heparin solution will be used for catheter lock in both catheter lumens as standard treatment, 1.9 mL in each catheter lumen will be infused after hemodialysis treatment during 3 months.
Study: NCT00705692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levamisole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00257920

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zemplar® injection
Description: 6 mcg QOD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hectorol® injection
Description: 3.6 mcg QOD
Study: NCT01261741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Each subject will receive memantine 10mg tablets once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each subject will receive matching placebo tablets once daily
Study: NCT00578071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Dose per cohort level (3.6, 4.8 or 6.0 mg/kg ), given intravenously (IV) days 1, 15 and 29 of radiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Dose per cohort level (500, 625 or 825 mg/m2) taken by mouth twice each day of radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Dose per cohort level (30, 40, or 50 mg/m2). Given IV one day each week during radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (RT)
Description: Daily for 6 weeks
Study: NCT01507974

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preventive antibiotic treatment- NITROFURANTOIN
Description: P.O NITROFURANTOIN 100 mg per day for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preventive antibiotic treatment- CEPHALEXIN
Description: P.O CEPHALEXIN 500 MG PER DAY FOR 6 WEEKS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PREVENTIVE TREATMENT- AMOXICILLIN
Description: P.O AMOXICILLIN 250 MG PER DAY FOR 6 WEEKS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PREVENTIVE TREATMENT- AMOXICILLIN AND CLAVULANATE POTASSIUM
Description: P.O AMOXICILLIN AND CLAVULANATE POTASSIUM, 875 MG PER DAY FOR 6 WEEKS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PREVENTIVE TREATMENT- CEFUROXIME
Description: P.O CEFUROXIME 250 MG PER DAY FOR 6 WEEKS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PREVENTIVE TREATMENT SULFAMETHOXAZOLE AND TRIMETHOPRIM
Description: P.O SULFAMETHOXAZOLE AND TRIMETHOPRIM 1 TAB PER DAY FOR 6 WEEKS
Study: NCT04247984

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 5 mg/kg intravenously administered on day 1 of a 2-week cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg intravenously administered on day 1 of a 2-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 2000mg/m2/day oral on day 1 to day 10 of a 2-week cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 180 mg/m2 intravenously administered on day 1 of a 2-week cycle.
Study: NCT03454529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Given PO
Study: NCT01456013

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RenalGuard Therapy
Description: Induced Diuresis with matched replacement
Study: NCT04173442

Intervention type: DRUG
Intervention: dupilumab
Description: Dupilumab cohort
Study: NCT01519284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067 5 mg
Description: BIA 9-1067 OPC, Opicapone 5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entacapone
Description: Entacapone 200 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo (four times a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo (four times a day)
Study: NCT04247984

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 400 mg/m2 intravenous bolus on day 1 and 2400 mg/m2 continuous infusion over 44 hours of a 2-week cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CF
Description: 300 mg/m2 intravenously administered on day 1 of a 2-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 150 mg/m2 intravenously administered on day 1 of a 2-week cycle.
Study: NCT02307643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1303 Low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1303 Low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1303 High dose
Study: NCT04346966

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Group
Description: Video Based Exercises 64 young adults aged 18-40, who are socially isolated due to coronavirus, will be included in this group. A video-based exercise protocol was created for individuals to participate in the study. Each exercise session is planned as 30 minutes 7 days a week for 6 weeks. The protocol was planned to start with warm-up exercises and end with cooling exercises. The exercise protocol has also been determined as a combination of aerobic exercises, strengthening and posture exercises. Individuals will be classified at 4 levels according to their physical activity levels and will be shared with volunteers according to their level of exercise. Volunteers will be evaluated before and after 6 weeks of exercise.
Study: NCT01764243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-4666
Description: low dose, high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-4666
Description: low dose, high dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00871741

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2202083A vaccine
Description: Intramuscular, three doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix hexa
Description: Intramuscular, three doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menjugate
Description: Intramuscular, two doses
Study: NCT00663832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589 (i.v. panobinostat)
Description: i.v. LBH589 dose levels: 10, 15, or 20 mg/m2~i.v. docetaxel 75 or 60 mg/m2~oral prednisone 5mg bid.~LBH589 i.v. administered on days 1 and 8 in combination with docetaxel i.v. on day 1 and prednisone p.o 5mg bid every day of a 21-day cycle
Study: NCT03119506

Intervention type: BEHAVIORAL
Intervention: Recess
Description: Recess timing and duration effects on lunch intake

Intervention type: BEHAVIORAL
Intervention: Recess
Description: Recess timing and duration effects on lunch intake
Study: NCT03307382

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpyGlass DS Cholangioscopy
Description: SpyGlass DS Cholangioscopy includes a 10 French diameter single use digital cholangioscope and a light source with the digital sensor. During ERCP with cholangioscopic exam, the cholangioscope would be first inserted through the working channel of the duodenoscope and subsequently passed into the bile duct for direct visualization of the bile duct mucosa. The visual impression (VI) of the biliary stricture will be assessed. Tissue acquisition of the biliary stricture will be performed by cholangioscopy directed biopsy (CDBx), and conventional brush cytology with or without intraductal biopsy.
Study: NCT01519284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo (four times a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo (four times a day)
Study: NCT03833921

Intervention type: DRUG
Group type: OTHER
Intervention: Abiraterone Acetate
Description: 1000 mg orally daily until disease progression

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone
Description: 5 mg oral low dose prednisone, twice daily
Study: NCT03119506

Intervention type: BEHAVIORAL
Intervention: Recess
Description: Recess timing and duration effects on lunch intake
Study: NCT03325504

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cultured Mesenchymal Stem Cells
Description: Cultured Mesenchymal Stem Cells obtained from expanded bone marrow

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cultured Mesenchymal Stem Cells
Description: Cultured Mesenchymal Stem Cells obtained from expanded bone marrow
Study: NCT01519284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo (four times a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa
Description: standard release levodopa/carbidopa 100/25 mg (single-dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa
Description: standard release levodopa/carbidopa 100/25 mg (single-dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa
Description: standard release levodopa/carbidopa 100/25 mg (single-dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa
Description: standard release levodopa/carbidopa 100/25 mg (single-dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067 15 mg
Description: BIA 9-1067 OPC, Opicapone 15 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067 30 mg
Description: BIA 9-1067 OPC, Opicapone 30 mg
Study: NCT03030911

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: The drug will be administered for sedation and its effect on basal metabolic rate will be investigated

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: The drug will be administered for sedation and its effect on basal metabolic rate will be investigated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: The drug will be administered in both groups

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: The drug will be administered in both groups
Study: NCT03325504

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous iliac crest graft
Description: Autologous iliac crest grafting
Study: NCT03030911

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Indirect calorimetry
Description: The device will be used for measurement of basal metabolic rate

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Indirect calorimetry
Description: The device will be used for measurement of basal metabolic rate
Study: NCT01884857

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol Succinate ER Tablets 50 mg
Description: 1\* 50 mg tablet once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Succinate ER Tablets 50 mg
Description: 1\* 50 mg tablet once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 'TOPROL-XL®' ER Tablets 50 mg
Description: 1 \* 50 mg tablet per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 'TOPROL-XL®' ER Tablets 50 mg
Description: 1 \* 50 mg tablet per day
Study: NCT00601796

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine Treatment
Description: We created a vaccine in which irradiated allogeneic lung adenocarcinoma cells are combined with a bystander K562 cell line transfected with hCD40L and hGM-CSF. By recruiting and activating dendritic cells, we hypothesized the vaccine would induce tumor regression in metastatic lung adenocarcinoma. Intradermal vaccine was given every 14 days x3, followed by monthly x3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (300 mg/m\^2 IV) was administered before 1st and 4th vaccines to deplete regulatory T-cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA)
Description: All-trans retinoic acid was given (150/mg/m\^2/day) after 1st and 4th vaccines to enhance dendritic differentiation.
Study: NCT02106455

Intervention type: DRUG
Intervention: Sodium risedronate
Description: Sodium risedronate tablets
Study: NCT01172834

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching
Description: A manual-driven group Health Coaching intervention. Once a week for 3 months.
Study: NCT00005060

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxotere-Cisplatin-5FU
Description: Preoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate surgery
Description: Immediate surgery followed by Taxotere-Cisplatin-5FU
Study: NCT01063816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: veliparib (ABT-888)
Description: Dosing orally twice daily starting Cycle 2 Day 1- through 21 adjusted for subsequent cohorts using a continuous reassessment method.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin will be dosed on Day 1 of each cycle, intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Dosing on Days 1 and 8 of each Cycle, intravenously.
Study: NCT01066195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iressa
Description: iressa 250mg per day every day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alimta
Description: alimta 500mg/m2 every 3 weeks